Search Results 81-90 of 8604 for Agmatine Sulfate

  1. BAY 1895344 Plus Topoisomerase-1 (Top1) Inhibitors In Patients With Advanced Solid Tumors, Phase I Studies With Expansion Cohorts In Small Cell Lung Carcinoma (SCLC), Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) And Pancreatic Adenocarcinoma (PDA) - Mayo Clinic

    BAY 1895344 Plus Topoisomerase-1 (Top1) Inhibitors In Patients With Advanced Solid Tumors, Phase I Studies With Expansion Cohorts In Small Cell Lung Carcinoma ( ...

  2. Study Of HPN536 In Patients With Advanced Cancers Associated With Mesothelin Expression - Mayo Clinic

    To assess the safety and tolerability at increasing dose levels of HPN536 in successive cohorts of patients with epithelial ovarian, fallopian tube, or primary ...

  3. Asthma medications: Know your options - Mayo Clinic

    Make a gift to honor and celebrate the contributions of our world-class doctors. Give Now · Find a doctor · Explore careers · Sign up for free e-newsletters ...

  4. https://www.mayoclinic.org/symptoms_all.xml

  5. Bacitracin and polymyxin b (ophthalmic route) - Side effects & dosage - Mayo Clinic

    This medicine is available only with your doctor's prescription. This product is available in the following dosage forms: Ointment. Back to top ...

  6. Open-label Study Of The Safety And Activity Of Oprozomib In Patients With Hematologic Malignancies - Mayo Clinic

    The purpose of this study is to determine the maximum tolerated dose (MTD), activity, and safety of oprozomib in patients with hematologic malignancies.

  7. https://www.mayoclinic.org/arabic_procedure_concepts.xml

  8. https://www.mayoclinic.org/~/media/410DC08A1B274C6594A11A1F485AAACE

  9. Study Of The Safety, Pharmacokinetics And Efficacy Of EDO-S101, In Patients With Advanced Solid Tumors - Mayo Clinic

    About this study. Tinostamustine (EDO-S101) is a new chemical entity, an AK-DAC (a first-in-class alkylating deacetylase inhibiting molecule) that, ...

  10. Axatilimab Plus Standard Of Care Therapy For The Prevention Of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation In Patients With Hematologic Cancer, ABRAXAS Trial - Mayo Clinic

    This phase II trial studies how well adding axatilimab to standard of care (SOC) therapy works in preventing graft versus host disease (GVHD) following ...